Pieris Pharmaceuticals, Inc. — FY 2014 Form 10-K
Filing identity: The supplied filing is for Pieris Pharmaceuticals, Inc., not “Pavella Therapeutics, Inc.” The company became a clinical-stage biopharmaceutical business through its December 17, 2014 acquisition of Pieris AG; Pieris AG is the accounting acquirer, so the financial statements principally reflect its historical operations. This report covers the year ended December 31, 2014, not fourth-quarter results alone.
Business context and reporting period
Pieris develops Anticalin protein therapeutics and had no approved products or product-sales revenue. Lead programs were PRS-080 for functional iron-deficiency anemia in chronic kidney disease and PRS-060 for asthma; oncology programs included PRS-110 and the 300-Series. The company’s reporting currency is the U.S. dollar and its principal operating currency is the euro.
Key financial metrics
| Metric | FY 2014 / December 31, 2014 | FY 2013 / December 31, 2013 |
|---|---|---|
| Revenue | $5.37 million | $12.43 million |
| Operating expenses | $12.56 million | $11.87 million |
| Operating income (loss) | $(7.20) million | $0.55 million |
| Net income (loss) | $(9.85) million | $0.07 million |
| Net loss per share | $(0.71) | Net income per share of $0.01 |
| Cash used in operations | $5.07 million | $3.08 million |
| Cash and cash equivalents | $18.47 million | $3.69 million |
| Total assets | $21.88 million | $7.28 million |
| Total liabilities | $3.88 million | $6.69 million |
Revenue came from collaboration and license arrangements and grants, not product sales. No gross-margin figure is presented. At year-end, current assets were $19.81 million and current liabilities were $3.54 million. The balance sheet showed a $1.27 million current bank loan; convertible stockholder loans had converted to equity, and no non-current bank loan remained. The company reported $18.01 million of stockholders’ equity and an accumulated deficit of $65.81 million.
Material changes versus FY 2013
- Revenue fell 57%, mainly as collaboration programs were handed to partners or ended, reducing recognition of upfront payments and research funding. Milestone revenue rose to $3.18 million from $1.13 million.
- Research and development expense declined to $5.60 million from $9.41 million, primarily due to lower external PRS-080 activity.
- General and administrative expense increased to $6.96 million from $2.46 million, principally reflecting the acquisition and private placement.
- Other expense increased to $2.65 million, including a $2.24 million noncash beneficial-conversion-feature charge related to bridge loans.
- The December private placement raised $13.56 million gross and $12.04 million net. The acquisition issued 20 million shares to former Pieris AG owners; the financing and transaction substantially changed the company’s ownership and capital structure.
Outlook, risks and unusual items
- Management expected year-end cash to fund operations and capital expenditures for at least 12 months, while stating that additional funding would be needed to continue development. No financial guidance or revenue forecast was provided.
- Management expected PRS-080 Phase I results by the end of 2015, intended to begin a PRS-060 Phase I trial in 2016, and planned to select a 300-Series candidate by the end of 2015. These are forward-looking plans, not reported outcomes.
- Major risks include early-stage clinical development, no product revenue, continuing losses and financing needs, competition, dependence on third-party clinical and manufacturing providers, foreign-currency exposure, and uncertain regulatory, reimbursement and intellectual-property outcomes.
- A material dispute with Technische Universität München concerns licensing payments: Pieris recorded a $0.33 million liability, while TUM asserted a substantially higher claim; the arbitration panel set the value in dispute at approximately $4.24 million. An adverse outcome could affect financial condition and access to licensed intellectual property.
- Management said disclosure controls were not effective because of a material weakness in internal control over financial reporting, including insufficient accounting and supervisory resources for complex U.S. GAAP and SEC reporting. Management did not provide an internal-control assessment for 2014; the auditor did not audit internal-control effectiveness.
- The filing describes the company as a voluntary filer and reports no established public market at June 30, 2014, alongside thin OTC trading. Investors should consider the resulting reporting and liquidity risks.
Most important facts for investors to verify
- Confirm the issuer’s identity and reconcile the filing’s share-count disclosures: year-end shares were 29,279,522, while the cover reports 29,429,522 outstanding as of March 27, 2015.
- Review the audited financial statements and cash-flow statement for cash runway, burn rate and debt repayment; the filing gives management’s “at least 12 months” estimate but stresses the need for further financing.
- Track the TUM arbitration, the potential effect on licensed technology, and whether any additional liability is required beyond the recorded reserve.
- Check progress and results against the stated PRS-080, PRS-060 and 300-Series development timelines, and assess whether partner-funded revenue and milestones continue.
- Monitor remediation of the material weakness, compliance with reporting obligations, and registration of resale shares. The filing describes resale registration obligations and possible cash penalties for certain failures.